Acreage Holdings, Inc.

The stock remains in a long-term downtrend and sits well below its 200-day average, with the 50-day also under the 200-day. That keeps the regime weak despite a rebound from the 52-week low, and the setup still looks like a distressed, high-volatility name rather than a confirmed base.

Street sentiment is mildly constructive, with a Buy consensus and a $0.40 target versus a sub-$0.13 share price. There have been no recent rating changes, so the view appears stable rather than improving, and the target still implies a sharp recovery from current levels.

Expect another loss-making quarter unless operating trends improve materially. The company has missed in 7 of 7 reported quarters, and the lone 2025 estimate calls for EPS of -$0.03 versus -$0.85 for 2024, so the key watch is whether losses narrow and revenue stabilizes.

No notable discretionary insider buying or selling. The recent activity is dominated by award-related grants and other non-open-market transactions, which read more like compensation and vesting flows than conviction signals.

Profitability remains weak, but gross margin is still a bright spot at 49.5%. Revenue fell 32.9% year over year, ROE was -135.6%, and the balance sheet carries $232.8 million of debt against $13.6 million of cash, leaving leverage elevated.

Against specialty cannabis peers, Acreage’s scale and retail footprint help, but profitability and leverage trail healthier operators. The valuation is deeply discounted on a market-cap basis, which fits a turnaround or restructuring profile more than a premium operating multiple.